Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...
Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial ...
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a ...
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t ...
Moderna notched a hard-fought FDA win earlier this month when the agency approved mFlusiva for adults aged 50 and older, ...
Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic ...
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...
Business was booming for Swiss pharma giant Novartis in the second quarter of 2025 with 11% net sales growth riding strong performance from major drugs. But one of the company’s “priority brands” ...
BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results